Presentation 1_Decreased brain-derived neurotrophic factor expression in chronic kidney disease: integrated clinical and experimental evidence.pptx by Juan Chen (61123)

“…</p>Conclusion<p>This study integrated meta-analysis, murine model validation, and single-cell transcriptomic profiling to demonstrate a significant reduction of BDNF in CKD. Furthermore, renal BDNF expression decreased locally, predominantly originating from proximal tubule cells, macrophages, and podocytes, possibly epigenetically inhibited by the upregulation of lnc RNA Bdnf-as.…”

An infographic outlining the data used for each analysis. by Shelby L. Sturrock (10751675)

Subjects:

Model-averaged coefficients, significance, and relative importance (RI) of the predictor variables for the GLMMs to evaluate effects on: (A) overall pollinator abundance; (B) fruit... by Carmelo Gómez-Martínez (9384385)

S1 Fig - by Miki Doi (15347878)

Subjects:

Semiannual analysis of monthly use of sterile blood transfer devices. by Miki Doi (15347878)

Subjects:

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

A representative ultrasound axis image. by Eun-Seon Yang (19751340)

Subjects:

BMI groups by SES. by Krystal Hunter (6820052)

Subjects:

BMISES_Data_Part2. by Krystal Hunter (6820052)

Subjects:

Logistic regression for LSES population. by Krystal Hunter (6820052)

Subjects:

Logistic regression for HSES population. by Krystal Hunter (6820052)

Subjects:

Logistic regression for overall population. by Krystal Hunter (6820052)

Subjects:

BMISES_Data_Part1. by Krystal Hunter (6820052)

Subjects:

Baseline characteristics of HSES/LSES population. by Krystal Hunter (6820052)

Subjects:

Baseline characteristics of overall population. by Krystal Hunter (6820052)

Subjects:

Diagram of study population. by Krystal Hunter (6820052)

Subjects:

A representative participant performing a Valsalva maneuver while checking the real-time respiratory pressure indicator. by Eun-Seon Yang (19751340)

Subjects:

Raw data. by Saeedeh Abbasi (9423189)

Subjects: